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‘Fibre’ means different things to different people. World, European and national 
definitions variously emphasise carbohydrate chain length, digestibility, and the 
particular monosaccharide components included. The European Food Safety 
Authority defines fibre as non-digestible carbohydrates with chain length of three or 
more monomeric units, and associated components of plant walls that are not 
carbohydrates, especially lignin1. This broad definition includes oligosaccharides, 
such as oligofructose, that are artificially derived from larger molecules and 
commonly added to food during production.  
 
Changes in definition should be considered when interpreting evidence of the health 
benefits of dietary fibre. In inflammatory bowel disease (IBD), dietary fibre has been 
of principal interest for its potential to reduce inflammation by modulating the 
microbiota. Prebiotics, a term coined by Glenn Gibson and Marcel Roberfroid, are 
non-digestible food ingredients that selectively stimulate a limited number of bacteria 
in the colon to improve health2. Where non-digestible carbohydrates can be 
fermented, the products of their metabolism include short-chain fatty acids which 
may stimulate regulatory T-cell proliferation3, contribute to colonic epithelial nutrition 
and improve intestinal health.  
 
The paper by Cox and co-workers4 addresses another consequence of fermentable 
carbohydrate ingestion: worsening of ‘functional-like gastrointestinal symptoms’. The 
authors have used this term to maintain the perceived boundary between 
inflammatory and non-inflammatory bowel disease but put simply these are 
‘symptoms’. The growing emphasis on patient reported outcomes (PROs) to 
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evaluate treatment means that more attention will be needed to issues that bother 
patients daily without ignoring important, but distant, outcomes such as a future need 
for surgery. The weight given to bowel frequency, abdominal pain and well-being in 
the Harvey Bradshaw Index or Crohn’s Disease Activity Index would lead to high 
scores in patients with active diarrhoea-predominant irritable bowel syndrome (IBS-
D). In IBD, there is increasing recognition that troubling symptoms can persist 
despite mucosal healing5. The link between dietary carbohydrates and symptoms is 
decades old but interest has resurged since the grouping of fermentable oligo-, di-, 
mono-saccharides and polyols under the term FODMAP by Peter Gibson and Sue 
Shepherd6.  
 
The patients recruited for this study were all in remission but continued to have 
symptoms consistent with functional bowel disorders according to Rome Foundation 
criteria. The investigators sought to tease out the role of different compounds within 
the FODMAP group: fructo-oligosaccharides (FOS, average monomeric chain length 
4), galacto-oligosaccharides (GOS) and sorbitol. The methodology mirrored the 
approach of Shepherd et al. used to demonstrate symptom induction by FODMAPs 
in IBS: brief, blind challenges in a crossover design with appropriate washout. As in 
IBS, FOS induced pain, bloating and flatulence with faecal urgency while upper tract 
symptoms did not vary. The lack of symptom induction with GOS and sorbitol may 
reflect the lower challenge doses used. While the rationale to model common dietary 
intake is understandable, doses were still in excess of daily intake described 
previously: around 0.4g for sorbitol, 2 g for GOS and 4 g for FOS with a further 4 g 
from fructose-based polysaccharides such as inulin. As a proof of principle it would 
be interesting to know the effect of equal doses.  This is particularly relevant for GOS 
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as one randomised controlled trial has shown relief of IBS symptoms when GOS was 
used as a prebiotic at a dose of 7 g/d7.  
 
Is an effect therefore specific to FOS, or can it be generalised to all FODMAPs? 
Does each carbohydrate need individual evaluation? The effect of ‘input’ (diet) on 
output ‘health’ is heavily dependent on the interwoven metabolic processes that 
occur in the colon microbiota; small adjustments may result in significant changes8. 
Inulin has been shown to induce colonic distension through gas generation, with 
consequent symptom severity relating to the sensitivity to distension of the 
individual9. There may be other reasons to suspect FOS. In the original FODMAP 
paper Gibson and Shepherd proposed mechanisms by which FODMAP fermentation 
might alter intestinal permeability6. A standard experimental model of horse laminitis 
feeds oligofructose 10 g/kg to the animals. Joint inflammation, accompanied by 
diarrhoea, occurs in 24 - 36 hours10. 
 
Before ‘Gibson’s Pendulum’ swings too far from prebiotic to FODMAP, the 
application of these data to clinical practice needs careful consideration. Laminitis 
can also be induced by starch overload and the equivalent human dose required of 
500g – 1kg reduces the likelihood of similarly gross observable effects in humans. 
Demonstration that dietary supplementation induces symptoms does not mean that 
dietary reduction will relieve them although evidence for such dietary advice in IBS 
continues to accrue. The gut lumen in IBD is a more dynamic environment; dietary 
interventions may have different effects at first induction of disease, during a flare 
and when in remission.  
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Cox et al. went to considerable lengths to ensure that their study was rigorous. Their 
CONSORT diagram shows the challenges of identifying suitable participants. All 
those included had previously reported benefit from a low FODMAP diet. Many 
patients in remission from IBD will not have symptoms and where patients have 
symptoms, many will respond to changes in immunomodulation rather than dietary 
adjustment. However, acknowledging that therapies used in functional bowel 
disorders may benefit patients with IBD can only widen the options available to 
clinicians. Priority setting partnerships with IBD patients in the United States and 
United Kingdom have both highlighted the need for evidence on the role of diet in 
symptom control. 
  
Many questions relating to the FODMAP diet remain. Cox et al. intensively monitored 
dietary intake but determining the FODMAP content of food remains a challenge. 
Beyond the original work of the Monash group, little analytical work has been done to 
measure the non-digestible, fermentable component of foods. More complete dietary 
databases are needed to allow comparison between sites and studies. Fermentable 
carbohydrates are not ingested in isolation so the effect of co-ingested products and 
the food matrix on fermentation needs to be understood. Lastly, efficacy of dietary 
advice needs to be tested in clinical trials before committing patients to a restrictive 
approach such as the low FODMAP diet, using endpoints of relevance to patients. 
The proof of the pudding will be in the eating.    
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